Liver transplant for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease versus other etiologies: A meta-analysis

Abstract

Background & Aims

Liver transplantation for hepatocellular carcinoma (HCC) in metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly being diagnosed and predicted to rise further. We compared outcomes of transplantation for MASLD-related HCC versus other etiologies (OE).

Methods

Databases were searched to identify studies comparing outcomes after transplantation MASLD-related HCC with OE-related HCC. Study data were pooled using random-effects modelling. Survival outcomes were analyzed using hazard ratio (HR) for overall survival (OS) and odds ratio (OR) for 1-,3-, and 5-years OS and disease-free survival (DFS).

Results

Ten retrospective comparative studies were identified including a total number of 51′761 patients (MASLD-related HCC=6′793, OE-related HCC=44′968). There were no significant differences in time-to-even survival (HR:0.93, CI_{95 %} 0.81–1.07,p = 0.29), 1-year (87.6% vs 88 %;OR:1.15; CI_{95 %}0.73–1.79,p = 0.55), 3-year (77.2% vs 76 %;OR:1.36;CI_{95 %}0.96–1.94,p = 0.08), or 5-year (67.7% vs 66.3 %;OR:1.08; CI_{95 %}0.77–1.53,p = 0.65) OS rates between the groups. DFS was comparable at 1-year (87.9% vs. 87 %; OR:1.07,p = 0.62), 3-years (77.6% vs. 73.6 %;OR:1.66,p = 0.13) and 5-year (68% vs. 65.6 %;OR:1.37,p = 0.39).

Conclusion

This meta-analysis of the best available evidence (Level 2a) demonstrated that liver transplantation for MASLD-related and OE-related HCC has comparable survival outcomes. Given the global rise in MASLD-related HCC as indication for transplantation, larger studies from other continents, including Europe and Asia, are needed to confirm our findings.